Dendritic cell potentiation

Details Dendritic cell potentiation Dendritic cell potentiation

2006-05-30

2006-05-30

Mosher, Mary E. (Department: 1648)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Binds eukaryotic cell or component thereof or substance...

C530S388150, C530S388200, C530S388220, C530S388700, C530S388730, C530S389100, C530S389600, C424S143100, C424S144100, C424S142100, C424S152100, C424S153100, C424S173100, C424S278100, C424S093100, C424S093700

Reexamination Certificate

active

07052694

ABSTRACT:
A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals.

REFERENCES:
patent: 2002/0160000 (2002-10-01), Wood et al.
patent: 2002/0164600 (2002-11-01), Freeman et al.
patent: 2003/0044768 (2003-03-01), Wood et al.
patent: 2003/0185827 (2003-10-01), Rodriguez et al.
patent: WO 01/83750 (2001-11-01), None
Aloisi et al., “Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1/Th2 cell restimulation,”Eur. J. Immunol., 1999, 29:2705-2714.
Anjuère et al., “Definition of Dendritic Cell Subpopulations Present in the Spleen, Peyer's Patches, Lymph Nodes, and Skin of the Mouse,”Blood, 1999, 93(2):590-598.
Asakura et al., “Targeting of IgMκ Antibodies to Oligodendrocytes Promotes CNS Remyelination,”J. Neuroscience, 1998, 18(19):7700-7708.
Banchereau and Steinman, “Dendritic cells and the control of immunity,”Nature, 1998, 392:245-252.
Banchereau et al., “Immunology of Dendritic Cells,”Annu. Rev. Immunol., 2000, 18:767-811.
Bieber et al., “Humoral autoimmunity as a mediator of CNS repair,”Trends in Neurosci., 2001, 24(11):S39-S44.
Block et al., “Monomeric Class I Molecules Mediate TCR/CD3ε/CD8 Interaction on the Surface of T Cells,”J. Immunol., 2001, 167:821-826.
Caux et al., “CD34+ Hematopoietic Progenitors from Human Cord Blood Differentiate Along Two Independent Dendritic Cell Pathways in Response to GM-CSF+ TNFα,”J. Exp. Med., 1996, 184:695-706.
Chen et al., “Tumor Immunogenicity Determines the Effect of B7 Costimulation on T Cell-mediated Tumor Immunity,”J. Exp. Med., 1994, 179:523-532.
Ciric et al., “Clonal evolution in Waldenstrom macroglobulinemia highlights functional role of B-cell receptor,”Blood, 2001, 97:321-323.
Cole et al., “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,”Monoclonal Antibodies and Cancer Therapy, 1985, Alan R. Liss, Inc., pp. 77-96.
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens,”Proc. Natl. Acad. Sci. USA, 1983, 80:2026-2030.
Critchfield et al., “T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis,”Science, 1994, 263:1139-1143.
Earnshaw et al., “Mammalian Caspases: Structure, Activation, Substrates, and Functions During Apoptosis,”Annu. Rev. Biochem., 1999, 68:383-424.
Fagnoni et al., “Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells,”Immunology, 1995, 85:467-474.
Fong and Engleman, “Dendritic Cells in Cancer Immunotherapy,”Annu. Rev. Immunol., 2000, 18:245-273.
Gallucci et al., “Natural adjuvants: Endogenous activators of dendritic cells,”Nature Medicine, 1999, 5(11):1249-1255.
Gallucci and Matzinger, “Danger signals: SOS to the immune system,”Curr. Opin. Immunol., 2001, 13:114-119.
Granucci et al., “Transcriptional reprogramming of dendritic cells by differentiation stimuli,”Eur. J. Immunol., 2001, 31:2539-2546.
Gunzer et al., “Antigen Presentation in Extracellular Matrix: Interactions of T Cells with Dendritic Cells Are Dynamic, Short Lived, and Sequential,”Immunity, 2000, 13:323-332.
Hogquist et al., “T Cell Receptor Antagonist Peptides Induced Positive Selection,”Cell, 1994, 76:17-27.
Humphrey et al., “The origin of follicular dendritic cells in the mouse and the mechanism of trapping of immune complexes on them,”Eur. J. Immunol., 1984, 14:859-864.
Inaba et al., “High Levels of a Major Histocompatibility Complex II-Self Peptide Complex on Dendritic Cells from the T Cell Areas of Lymph Nodes,”J. Exp. Med., 1997, 186(5):665-672.
Ingulli et al., “In Vivo Detection of Dendritic Cell Antigen Presentation to CD4+ T Cells,”J. Exp. Med., 1997, 185(12):2133-2141.
Johnson et al., “Prevalent Class I-Restricted T-Cell Response to the Theiler's Virus Epitope Db:VP2121-130in the Absence to Endogenous CD4 Help, Tumor Necrosis Factor Alpha, Gamma Interferon, Perforin, or Costimulation through CD28,”J. Virology, 1999, 73(5):3702-3708.
Johnson et al., “Preservation of motor function by inhibition of CD8+ virus peptide-specific T cells in Theiler's virus infection,”FASEB J., 2001, 15:2760-2762.
Josien et al., “TRANCE, a Tumor Necrosis Factor Family Member, Enhances the Longevity and Adjuvant Properties of Dendritic Cells In Vivo,”J. Exp. Med., 2000, 191(3):495-501.
Kanto et al., “Ceramide Mediates Tumor-Induced Dendritic Cell Apoptosis,”J. Immunol., 2001, 167:3773-3784.
Koch et al., “Effective Enrichment of Murine Epidermal Langerhans Cells by a Modified (Mismatched) Panning Technique,”J. Invest. Dermatol., 1992, 99:803-807.
Köhler and Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature, 1975, 256:495-497.
Kozbor and Roder, “The production of monoclonal antibodies from human lymphocytes,”Immunology Today, 1983, 4(3):72-79.
Lang et al., “Isolation and Characterization of a Human Monoclonal Antibody That Recognizes Epitopes Shared byPseudomonas aeruginosaImmunotype 1, 3, 4, and 6 Lipopolysaccharides,”Infection and Immunity, 1989, 57(12):3851-3855.
Latchman et al., “PD-L2 is a second ligand for PD-1 and inhibits T cell activation,”Nature Immunol., 2001, 2(3):261-268.
Leenen et al., “Heterogeneity of Mouse Spleen Dendritic Cells: In Vivo Phagocytic Activity, Expression of Macrophage Markers, and Subpopulation Turnover,”J. Immunol., 1998, 160:2166-2173.
Lu et al., “Increased Apoptosis of Immunoreactive Host Cells and Augmented Donor Leukocyte Chimerism, Not Sustained Inhibition of B7 Molecule Expression are Associated with Prolonged Cardiac Allograft Survival in Mice Preconditioned with Immature Donor Dendritic Cells Plus Anti-CD40L mAb,”Transplantation, 1999, 68(6):747-757.
Lutz et al., “An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow,”J. Immunol. Meth., 1999, 223:77-92.
Maldonado-López et al., “CD8α and CD8α Subclasses of Dendritic Cells Direct the Development of Distinct T Helper Cells In Vivo,”J. Exp. Med., 1999, 189(3):587-592.
Maraskovsky et al., “Dramatic Increase in the Numbers of Functionally Mature Dendritic Cells in Flt3 Ligand-treated Mice: Multiple Dendritic Cell Subpopulations Identified,”J. Exp. Med., 1996, 184:1953-1962.
Matsue et al., “Dendritic Cells Undergo Rapid Apoptosis In Vitro During Antigen-Specific Interaction with CD4+ T Cells,”J. Immunol., 1999, 162:5287-5298.
Mayordomo et al., “Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity,”Nature Medicine, 1995, 1(12):1297-1302.
Miller et al., “Monoclonal Autoantibodies Promote Central Nervous System Repair in an Animal Model of Multiple Sclerosis,”J. Neurosci., 1994, 14(10):6230-6238.
Miller et al., “Multi-organ Reactivity of a Monoclonal Natural Autoantibody That Promotes Remyelination in a Mouse Model of Multiple Sclerosis,”J. Histochem. Cytochem., 1996, 44(9):1005-1011.
Mitsunaga et al., “Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease,”FASEB J., 2002, 16(10):1325-1327.
Monks et al., “Three-dimensional segregation of supramolecular activation clusters in T cells,”Nature, 1998, 395:82-86.
Murphy et al., “Induction by Antigen of Intrathymic Apoptosis of

Affiliated with

Also associated with

Rating

Dendritic cell potentiation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dendritic cell potentiation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dendritic cell potentiation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3630813